NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOGRAFIN-76 is a high-osmolar contrast medium containing diatrizoate meglumine used for radiographic imaging procedures. It is administered by injection to visualize internal organs and blood vessels during diagnostic imaging studies. The drug works by absorbing X-rays more effectively than surrounding tissue, providing enhanced contrast for medical visualization.
LOE Approaching
As LOE approaches on this legacy diagnostic imaging product, commercial teams are likely operating in maintenance or wind-down mode with smaller support infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, career growth on RENOGRAFIN-76 is severely limited. This product is suited only for professionals managing legacy portfolios or seeking stable, low-intensity roles in maintenance commercial operations.
Brand ManagerField Sales Representative
Worked on RENOGRAFIN-76 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.